Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Milestones in Antiviral Drug Development

Version 1 : Received: 4 December 2023 / Approved: 5 December 2023 / Online: 5 December 2023 (14:46:01 CET)

A peer-reviewed article of this Preprint also exists.

De Clercq, E. Selected Milestones in Antiviral Drug Development. Viruses 2024, 16, 169. De Clercq, E. Selected Milestones in Antiviral Drug Development. Viruses 2024, 16, 169.

Abstract

In this review article will be described the (wide) variety of approaches that I envisaged to develop a specific therapy of viral infections: (i) interferon and its inducers, (ii) HSV, VZV and CMV inhibitors, (iii) NRTIs (nucleoside reverse transcriptase inhibitors), NtRTIs (nucleotide reverse transcriptase inhibitors) and NNRTIs (non-nucleoside reverse transcriptase inhibitors) as HIV inhibitors, (iv) NtRTIs as HBV inhibitors and finally, (v) the transition of an HIV inhibitor to a stem cell mobilizer, as exemplified by AMD-3100 (Mozobil®).

Keywords

HIV; HBV; HSV; VSV; CMV; AIDS; ANPs; NRTIs; NtRTIs; NNRTIs

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.